drugset / Trial / NCT04470804

Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA

NCT04470804

Phase 4 Completed 56 enrolled Bing Han
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Pure red cell aplasia (PRCA) is a kind of anemia characterized by severe reticulocytopenia and obvious bone marrow erythroblastic cells decreased. Cyclosporine A and /or steroids are the first line therapy but some patients were refractory or intolerance to the treatment. The effects of the second line therapy are also not satisfactory and sometimes not available. The investigators aim to explore the efficacy and side-effect of sirolimus for newly diagnosed primary acquired PRCA.

Timeline

Start
2020-07-01
Primary completion
2022-07-30
Completion
2022-07-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclosporine Peptide 4 mg/kg
Subject Sirolimus Small molecule 2 mg